Vigilance des essais cliniquesDéclaration des erreurs médicamenteuses dans les recherches portant sur le médicament : place du pharmacien des essais cliniques ? Medication errors reporting in drug clinical trials: role of the clinical research pharmacist?Erreurs médicamenteuses dans les essais cliniques

or dissemination syndrome. Safety was evaluated describing adverse events (AE). Results 35 COVID-19 patients from endemic areas were admitted and treated with ivermectin 6 mg/8 hours for 2 days. 52% of patients were women, with an average age of 42.84±11.38 years. The patients treated with ivermectin were from Latin America, and the most frequent countries were: 48% Bolivia, 24% Nicaragua, 12% Ecuador, 8% Colombia and 8% Peru. Immunosuppressive treatment was: 83% dexamethasone 6 mg/24 hours, 14% methylprednisolone bolus 250 mg, 12% tocilizumab 400 mg and 3% no immunosuppressive treatment. Three (9%) of the patients presented with positive S stercoralis serology. However, they did not develop S stercoralis hyperinfection or dissemination syndrome. Furthermore, no patient had eosinophilia, with an average eosinophiles blood count of 0.04±0.09×10 3 /mg. None of the patients had adverse events. Conclusion and relevance Prophylactic treatment with ivermectin was safe. Patients from endemic areas who should start immunosuppressive treatment as soon as possible could be treated prophylactically with ivermectin. Nevertheless, the number of patients and positive cases were small and more studies are needed to generate evidence.

Background and importance Recent studies have indicated that androgen deprivation therapy (ADT) increased the dementia risk in prostate cancer (PCa) patients. Phosphodiesterase 5 inhibitors (PDE5i) with nitric oxide mediated vasodilation can increase blood flow in the brain. However, no current studies have explored the association between PDE5i exposure and dementia in PCa patients treated with ADT.

Conclusion and relevance HAMC were widely prescribed. Benzodiazepines were the therapeutic group most prescribed from the HAMC list in our population, followed by antiplatelets and antipsychotics. The HAMC list is a useful tool for a first approach in the detection of patients who may be at a higher risk of serious harms if medication errors occur. Implementation of specific safe practices for those drugs could reduce potential or real errors in these patients.

No abstract